TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06084416: A Study of Sovilnesib in Subjects With Ovarian Cancer

Sponsor: Volastra Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$4,272,576

Rescue Site Savings

+$2,827,440

Unlock Full NCT06084416 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06084416 Rescue Dossier →